ArticleBreast cancer research and treatment2023
Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.
Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes.Breast cancer (Tokyo, Japan) · 2026Article
- Annual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Long-term Outcomes of Slowly Proliferating Luminal A-like Invasive Lobular Carcinoma Versus Invasive Carcinoma of No Special Type.Journal of breast cancer · 2026Article
- Trends in thyroid surgery in Japan from 2014 to 2023: report on the National Clinical Database.Surgery today · 2026Article
- Molecular and Biological Features of Invasive Lobular Carcinoma: Toward New Treatment Strategies.Annals of surgical oncology · 2026Review
- Differential prognostic significance of tumor size and node in invasive lobular carcinoma of breast.Breast cancer research : BCR · 2025Article
- Retrospective insights: clinical characteristics and survival in 403 ILC cases from China.BMC cancer · 2025Article
- Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status.Breast cancer (Tokyo, Japan) · 2025Article
- Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.Breast cancer (Tokyo, Japan) · 2025Article
- Novel nomograms for predicting overall survival and cancer-specific survival in invasive lobular carcinoma of the breast.Discover oncology · 2025Article
- Investigation of Risk Factors and Development and Validation of a Nomogram for Predicting Overall Survival in Breast-Invasive Lobular Carcinoma.Breast care (Basel, Switzerland) · 2025Article
- Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression.Breast cancer (Tokyo, Japan) · 2025Article
- Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.Breast cancer (Tokyo, Japan) · 2024Article
- 2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.Breast cancer (Tokyo, Japan) · 2024Article
- Annual report of the Japanese Breast Cancer Registry for 2019.Breast cancer (Tokyo, Japan) · 2024Article
- Is mixed invasive ductal lobular carcinoma distinct from invasive lobular carcinoma?Breast cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMany studies have shown that the prognosis of invasive lobular carcinoma (ILC) is better than that of invasive ductal carcinoma (IDC). However, both disorders exhibit different prognoses according to molecular subtype, and the prognosis of ILC subtypes might depend on their hormone receptor positivity rate. This study clarified the prognosis of ILC and IDC in each subtype and examined the effectiveness of adjuvant chemotherapy (CT) in luminal ILC.
methodsWe planned the analysis using data from the Breast Cancer Registry in Japan. Because it was presumed that there are differences in characteristics between ILC and IDC, we created matched cohorts using exact matching to compare their prognoses. We compared the prognosis of ILC and IDC for each subtype. We also compared the prognosis of luminal ILC between the CT and non-CT groups.
resultsFor all subtypes, the disease-free survival (DFS) and overall survival (OS) of ILC were poorer than those of IDC. In the analysis by each subtype, no statistically significant difference was found in DFS and OS in luminal human epidermal growth factor 2 (HER2), HER2, and triple-negative cohorts; however, luminal ILC had significantly poorer DFS and OS than luminal IDC. The CT effects on the prognosis of luminal ILC were greater in more advanced cases.
conclusionLuminal ILC had a poorer prognosis than luminal IDC, contributing to the worse prognosis of ILC than that of IDC in the overall cohort. Different therapeutic approaches from luminal IDC are essential for a better prognosis of luminal ILC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.